Residency · Residency · Urology

Metabolic Evaluation and Medical Management of Nephrolithiasis

Epidemiology

Nephrolithiasis, or kidney stone disease, affects approximately 10-15% of individuals over their lifetime, and this prevalence is increasing. Historically, men were more commonly affected than women, with a male-to-female ratio of about 3:1; however, this gap is narrowing and now approaches 1.5:1. The peak incidence occurs between 40 and 60 years of age. Without preventive measures, about half of patients experience stone recurrence within five years. Geographic variation exists, with a higher prevalence in the southeastern United States, known as the "stone belt." Risk factors such as obesity, diabetes, and metabolic syndrome independently increase the likelihood of stone formation.

Stone Composition

Calcium Oxalate (70-80%)

Calcium oxalate stones are the most common type encountered. They exist primarily in two forms: calcium oxalate monohydrate (whewellite), which is hard and radiodense on imaging, and calcium oxalate dihydrate (weddellite), characterized by bipyramidal crystals and often found mixed with the monohydrate form.

Calcium Phosphate (10-15%)

Calcium phosphate stones include brushite (calcium hydrogen phosphate), which is hard and resistant to shock wave lithotripsy (SWL), and hydroxyapatite, which tends to form in urine with a higher pH, typically above 6.5. These stones are often associated with distal renal tubular acidosis (type 1 RTA).

Uric Acid (5-10%)

Uric acid stones are radiolucent on plain radiographs but visible on computed tomography (CT). They form in acidic urine, generally when the pH is below 5.5. Conditions associated with uric acid stones include gout, metabolic syndrome, chronic diarrhea, and myeloproliferative disorders. Notably, uric acid stones are the only type amenable to medical dissolution.

Struvite (Magnesium Ammonium Phosphate) (5-10%)

Struvite stones, also known as infection stones, develop in the presence of urease-producing bacteria such as Proteus, Klebsiella, and Pseudomonas species. These stones can form large staghorn calculi and are associated with alkaline urine, typically with a pH above 7.2.

Cystine (1-2%)

Cystine stones result from an autosomal recessive defect in the transport of dibasic amino acids, involving mutations in the SLC3A1 and SLC7A9 genes. They produce characteristic hexagonal crystals visible on urinalysis and yield a positive nitroprusside test. These stones have an extremely high recurrence rate.

<image>Photographs and crystal morphology of the five major stone types: calcium oxalate, calcium phosphite, uric acid, struvite, and cystine</image>

Stone Analysis

All stones that are passed spontaneously or retrieved surgically should be sent for analysis using infrared spectroscopy or X-ray diffraction. Determining the precise stone composition is essential because it guides the metabolic evaluation and informs the prevention strategy. Visual inspection alone is unreliable and should not be used to determine stone type.

Metabolic Evaluation

Indications for Full Metabolic Workup

A comprehensive metabolic workup is indicated for all recurrent stone formers. It is also recommended for first-time stone formers who have high-risk features, including the presence of non-calcium stones (such as uric acid, cystine, or struvite stones), a family history of nephrolithiasis, a solitary kidney, pediatric patients, nephrocalcinosis, or systemic diseases such as inflammatory bowel disease (IBD), gout, hyperparathyroidism, or obesity/bariatric surgery.

Basic Serum Studies

Initial laboratory evaluation includes a comprehensive metabolic panel to assess serum calcium, potassium, bicarbonate, creatinine, and blood urea nitrogen (BUN). Intact parathyroid hormone (PTH) should be measured if hypercalcemia is present to evaluate for primary hyperparathyroidism. Serum uric acid is also assessed, and phosphorus levels should be checked if calcium phosphate stones are suspected.

24-Hour Urine Collection

At least one 24-hour urine collection is necessary, with two collections preferred for reproducibility. Collections should be performed while the patient is on their typical diet rather than a modified one. Key analytes measured include urine volume, calcium, oxalate, citrate, uric acid, sodium, and pH. Target values are a urine volume greater than 2.5 liters per day; calcium less than 250 mg/day in men and less than 200 mg/day in women; oxalate below 40 mg/day; citrate above 320 mg/day in women and 450 mg/day in men; uric acid below 700 mg/day in men and 600 mg/day in women; sodium less than 150 mEq/day as a proxy for dietary salt intake; and an ideal urine pH between 5.8 and 6.2. Supersaturation indices for calcium oxalate, calcium phosphate, and uric acid should also be evaluated, with targets of less than 2, less than 1, and less than 1 respectively.

<image>Flowchart for metabolic workup of nephrolithiasis showing decision points based on stone composition and 24-hour urine results</image>

Dietary and Lifestyle Modifications (First-Line for All Stone Formers)

The cornerstone of management for all stone formers involves dietary and lifestyle modifications. Patients should aim for a urine output exceeding 2.5 liters per day, primarily through increased water intake; lemonade can be used as a source of citrate. Sodium intake should be restricted to less than 2,300 mg per day because high sodium consumption increases urinary calcium excretion. Contrary to intuition, dietary calcium should not be restricted; an intake of 1,000 to 1,200 mg per day is recommended, as calcium binds oxalate in the gut and reduces its absorption, a finding supported by the DASH trial. Animal protein intake should be moderated to 0.8 to 1.0 grams per kilogram per day, which helps reduce uric acid production, increases urinary citrate, and raises urine pH. For patients with hyperoxaluria, high-oxalate foods such as spinach, rhubarb, nuts, chocolate, and tea should be avoided. Increasing the consumption of fruits and vegetables is encouraged because their natural alkali load raises urinary citrate levels.

Medical Therapy by Abnormality

Hypercalciuria

Thiazide diuretics are the first-line pharmacologic treatment for hypercalciuria. Common agents include hydrochlorothiazide 25 mg twice daily, chlorthalidone 25 mg once daily, or indapamide 2.5 mg once daily. These drugs increase calcium reabsorption in the distal tubule, thereby reducing urinary calcium excretion and decreasing stone recurrence by 40-50%, as demonstrated in randomized controlled trials. Potassium levels should be monitored during therapy, and potassium supplementation with potassium chloride or concurrent use of potassium citrate may be necessary to prevent hypokalemia. It is important to rule out primary hyperparathyroidism in patients with hypercalcemia and elevated PTH, as parathyroidectomy may be indicated.

Hypocitraturia

Potassium citrate is the treatment of choice for hypocitraturia, typically dosed at 30 to 60 mEq per day in divided doses. It inhibits the crystallization of calcium oxalate and calcium phosphate and raises urine pH, which is beneficial for patients with uric acid stones but requires caution in those with calcium phosphate stones due to the risk of stone formation at higher pH. Gastrointestinal side effects are common, but wax-matrix tablets improve tolerability. For patients intolerant to potassium citrate, Crystal Light lemonade can serve as an alternative citrate source.

Hyperoxaluria

Management of hyperoxaluria includes dietary oxalate restriction and calcium supplementation with meals to bind oxalate in the gut. In cases of enteric hyperoxaluria, such as in patients with inflammatory bowel disease, short bowel syndrome, or after bariatric surgery, additional therapies like cholestyramine and medium-chain triglycerides may be used. Primary hyperoxaluria type 1 responds to pyridoxine (vitamin B6), and lumasiran (ALN-GO1) is an emerging treatment for this condition.

Hyperuricosuria

Allopurinol, dosed at 100 to 300 mg daily, reduces uric acid excretion and has been shown to decrease calcium oxalate stone recurrence when hyperuricosuria is the sole metabolic abnormality. Patients should be monitored for hypersensitivity reactions, and HLA-B*5801 testing is recommended in populations at risk for severe adverse effects.

Uric Acid Stones (Specific Management)

Uric acid stones are unique in that they can be dissolved medically through urinary alkalinization. Potassium citrate is used to raise urine pH to a target range of 6.0 to 6.5. Urine pH should be monitored regularly with pH paper or a digital pH meter. Maintaining adequate fluid intake to dilute the urine is essential. Allopurinol may be added if hyperuricemia or hyperuricosuria is present.

Cystine Stones

Management of cystine stones requires aggressive hydration to achieve a urine output greater than 3 liters per day, as dilution is the most critical factor in preventing stone formation. Urinary alkalinization with potassium citrate to maintain a urine pH above 7.0 increases cystine solubility. Tiopronin (Thiola) is the first-line thiol-binding agent and is preferred over D-penicillamine due to a better side effect profile. D-penicillamine is reserved as a second-line agent because of its significant toxicities, including rash, proteinuria, and marrow suppression. Captopril has been proposed to form a soluble captopril-cystine complex, but clinical evidence supporting its use is weak.

Struvite Stones

The primary treatment for struvite stones is complete stone removal, often via percutaneous nephrolithotomy (PCNL). Directed antibiotic therapy based on urine culture is essential to eradicate infection. Acetohydroxamic acid (AHA), a urease inhibitor, may be used adjunctively to prevent recurrence when complete stone clearance is not achievable. However, its use is limited by side effects such as headache, tremor, deep vein thrombosis, and hemolytic anemia.

<image>Table summarizing medical therapies for each metabolic abnormality in nephrolithiasis with dosing and monitoring</image>

Monitoring and Follow-Up

After initiating therapy, a repeat 24-hour urine collection should be performed at 3 to 6 months to assess treatment response. Active stone formers require annual metabolic follow-up. Imaging surveillance with low-dose CT or renal ultrasound should be conducted annually or biannually. Patient compliance with dietary and medical therapy remains the major barrier to successful prevention of stone recurrence.

Special Populations

Pediatric stone formers warrant a full metabolic evaluation due to their high recurrence rates. Patients who have undergone bariatric surgery are prone to enteric hyperoxaluria and require high fluid intake, calcium supplementation, and oxalate restriction. Those with inflammatory bowel disease or short bowel syndrome often have enteric hyperoxaluria, hypocitraturia, and low urine volume. Medullary sponge kidney predisposes patients to calcium stones and nephrocalcinosis. In pregnancy, imaging and treatment options are limited, so management focuses on hydration and urine straining.

Clinical Pearls

Stone analysis is essential for every patient because stone composition directly influences prevention strategies. Paradoxically, restricting dietary calcium increases stone risk, as demonstrated by Borghi et al. in the NEJM 2002. High urinary sodium is one of the most modifiable risk factors because it directly increases urinary calcium excretion. Potassium citrate simultaneously addresses two risk factors by correcting low citrate levels and low urine pH. Thiazide diuretics lose efficacy in the context of high sodium intake, making dietary sodium restriction synergistic with pharmacotherapy. Uric acid stones are unique in being the only type that can be dissolved with medical therapy through alkalinization. Finally, 24-hour urine collections should be performed while patients consume their usual diet rather than an idealized one to obtain accurate metabolic data.

References

• AUA/Endourology Society Guideline on Surgical Management of Stones, 2016 (amended 2022)
• AUA Medical Management of Kidney Stones Guideline, 2014 (amended 2022)
• Pearle MS, et al. "Medical management of kidney stones: AUA guideline." J Urol. 2014;192(2):316-324.
• Borghi L, et al. "Comparison of two diets for the prevention of recurrent stones." NEJM. 2002;346(2):77-84.
• Ferraro PM, et al. "Dietary and lifestyle risk factors for kidney stones." NEJM. 2023.
• Campbell-Walsh-Wein Urology, 12th Edition, Chapter on Urinary Lithiasis

Read this lecture as Markdown